Paper Details

  1. Home
  2. Paper Details

Emerging immune targets for the treatment of multiple myeloma.

Author: AnwerFaiz, IftikharAhmad, KurtinSandra E, McBrideAli, MushtaqAdeela, SohailAtif, TennetiPavan, WarraichZabih

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This review explores new immunotherapy approaches for multiple myeloma (MM) that are not yet approved by the US FDA. Some promising treatments include monoclonal antibodies, like isatuximab, siltuximab, and pembrolizumab, which have shown effectiveness when used in combination with other therapies. However, other antibodies used alone, such as BI-505 and siltuximab, have not shown success. Another promising approach involves CAR T-cell therapy, which uses genetically engineered immune cells to target cancer cells. Preliminary results with CAR T-cell therapy for advanced MM are very encouraging. The future of using antibodies and T-cell therapy for MM looks promising.
Paper Details　
Original Abstract of the Article :
We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuxima...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810847/

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: A Complex and Challenging Disease

Multiple myeloma, a cancer affecting plasma cells in the bone marrow, presents a formidable challenge for healthcare professionals. This research explores the emerging frontiers in multiple myeloma treatment, focusing on innovative immune-based therapies. The study meticulously reviews a wide array of potential treatments, including monoclonal antibodies, CAR T-cell therapy, and other promising approaches. Imagine this as a meticulous exploration of a vast desert of possibilities, seeking a path toward effective and safe treatment.

The study highlights the promising results achieved with certain monoclonal antibodies, such as isatuximab and siltuximab, in combination therapy. The study also points to the remarkable potential of CAR T-cell therapy, showcasing its ability to achieve complete response in advanced cases. These findings signify a shift in the landscape of multiple myeloma treatment, offering a glimmer of hope for patients facing this challenging disease.

A New Dawn in Multiple Myeloma Treatment

This research highlights the remarkable advancements in multiple myeloma treatment, showcasing the potential of immune-based therapies to reshape the landscape of care. These innovative approaches offer a ray of hope for patients, providing a more targeted and potentially more effective way to combat this challenging disease.

Navigating the Desert of Uncertainty: Hope on the Horizon

The desert of multiple myeloma can be daunting, but the emergence of these novel therapies offers a beacon of hope. While challenges remain, the ongoing research and development of these immune-based therapies are paving the way toward a future where multiple myeloma is effectively managed and potentially even cured. This research is a testament to the unwavering efforts of researchers and clinicians, committed to finding innovative solutions for those affected by this disease.

Dr. Camel's Conclusion

This comprehensive review highlights the exciting advancements in multiple myeloma treatment, showcasing the potential of immune-based therapies to transform the lives of patients facing this challenging disease.

Date :
  1. Date Completed 2019-05-14
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

29421983

DOI: Digital Object Identifier

PMC5810847

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.